Skip to main content
Clinical Trials/ACTRN12612001019897
ACTRN12612001019897
Completed
未知

The effect of yoga on pain and sleep disturbance in rheumatoid arthritis patients – a pilot randomised controlled trial.

Dr Simon Stebbings0 sites28 target enrollmentSeptember 20, 2012

Overview

Phase
未知
Intervention
Not specified
Conditions
Rheumatoid arthritis
Sponsor
Dr Simon Stebbings
Enrollment
28
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 20, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dr Simon Stebbings

Eligibility Criteria

Inclusion Criteria

  • Participants need to have a clinical diagnosis of rheumatoid arthritis, according to the American College of Rheumatology classification criteria; be aged 18 years or older; be able to understand written and spoken English; have baseline pain equal to or greater than 3 on a 10\-point numeric rating scale; have baseline sleep disturbance equivalent to greater than 30 minutes to fall asleep or greater than 30 minutes awakened during the night; have had a stable medication regime for the previous 8 weeks; be able to self\-mobilize in and out of a chair; agree to refrain from receiving or commencing other complementary and alternative medicine treatments or exercise programmes for the duration of the intervention; agree to notify researchers of any change in usual medications during the intervention, especially analgesics; and provide written informed consent.

Exclusion Criteria

  • Potential participants will be excluded if they already practice or have regularly practiced yoga in the previous 6 months; have recently had or expect to have surgery within 6 months of screening; have a medical condition, physical, or mental health impairment apart from RA that precludes their safe participation in exercise; are unable to commit to availability for the full course of the intervention; or have had or expect to have intra\-articular steroid injections within 4 weeks of screening.

Outcomes

Primary Outcomes

Not specified

Similar Trials